{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:12:17Z","timestamp":1788667937370,"version":"build-2803163510"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Small cell lung cancer is one of the most aggressive malignancies, characterized by rapid tumor growth, early metastatic spread and extremely poor survival. Although most patients initially respond to platinum-based chemotherapy, relapse is almost inevitable and treatment options at recurrence remain limited. The recent introduction of immune checkpoint inhibitors has provided only modest clinical benefit, largely due to the fact that these tumors are immunologically cold. These limitations highlight the urgent need to better understand the molecular features of small cell lung cancer in order to identify more effective therapeutic strategies. In this review, we summarize current knowledge of the molecular landscape of small cell lung cancer, with particular emphasis on transcriptome-based classifications that have identified four major molecular subtypes defined by distinct transcriptional regulators and gene expression programs. We discuss how these classifications have improved the biological understanding of the disease and stimulated efforts to develop subtype-specific therapeutic strategies. At the same time, we highlight important limitations of this framework, including the remarkable transcriptional plasticity of tumor cells, which allows dynamic transitions between subtypes and may contribute to therapeutic resistance. To address these challenges, we examine additional molecular features that may represent more stable vulnerabilities, including recurrent genomic alterations, such as the widespread loss of tumor suppressor genes or oncogene amplifications through extrachromosomal DNA. We also discuss emerging approaches aimed at identifying novel context-specific cancer dependencies, including genome-scale functional screens in vitro and in vivo and genetic restraint analyses. Finally, we consider the growing potential of liquid biopsy strategies, which exploit the high level of circulating tumor DNA in patients with this disease to detect clinically relevant genomic alterations and monitor tumor evolution. Overall, this review highlights both the opportunities and challenges associated with molecular stratification in small cell lung cancer. The integration of transcriptional classifications with genomic and functional approaches may help identify more robust therapeutic vulnerabilities and guide the development of more effective treatments for this highly aggressive disease.<\/jats:p>","DOI":"10.1186\/s40364-026-00991-3","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:15:55Z","timestamp":1788617755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating molecular subtypes, genomics and functional dependencies to identify context-specific therapeutic vulnerabilities in small cell lung cancer"],"prefix":"10.1186","volume":"14","author":[{"given":"Ilaria","family":"Cassotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Fiume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gandellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia Tiziana","family":"Storlazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"issue":"1","key":"991_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","volume":"18","author":"Q Wang","year":"2023","unstructured":"Wang Q, Li M, Zhang X, Chen H, Xu Y, Liu Y, et al. SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection. J Thorac Oncol. 2023;18(1):31\u201346. https:\/\/doi.org\/10.1016\/j.jtho.2022.10.002.","journal-title":"J Thorac Oncol"},{"key":"991_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.omto.2021.02.004","volume":"20","author":"A Schwendenwein","year":"2021","unstructured":"Schwendenwein A, Megyesfalvi Z, Barany N, Valko Z, Bugyik E, Lang C, et al. Molecular profiles of small cell lung cancer subtypes: therapeutic implications. Mol Ther Oncolytics. 2021;20:470\u201383. https:\/\/doi.org\/10.1016\/j.omto.2021.02.004.","journal-title":"Mol Ther Oncolytics"},{"issue":"7","key":"991_CR3","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1158\/2159-8290.CD-22-0620","volume":"13","author":"S Sivakumar","year":"2023","unstructured":"Sivakumar S, Chong L, Pham D, Lee J, Tan M, Wang L, et al. Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histologic transformation. Cancer DiscovCancer Discov. 2023;13(7):1572\u201391. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0620.","journal-title":"Cancer DiscovCancer Discov"},{"issue":"12","key":"991_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nrc.2017.87","volume":"17","author":"AF Gazdar","year":"2017","unstructured":"Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17(12):725\u201337. https:\/\/doi.org\/10.1038\/nrc.2017.87.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"991_CR5","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","volume":"19","author":"AKP Ganti","year":"2021","unstructured":"Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D\u2019Amico TA, et al. Small cell lung cancer, version 2. 2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network. 2021;19(12):1441\u201364. https:\/\/doi.org\/10.6004\/jnccn.2021.0058.","journal-title":"J Natl Compr Cancer Network"},{"key":"991_CR6","doi-asserted-by":"publisher","unstructured":"Drapkin BJ, Rudin CM. Advances in small-cell lung cancer (SCLC) translational research. Cold Spring Harb Perspect Med. 2021;11(4):a038240. https:\/\/doi.org\/10.1101\/cshperspect.a038240.","DOI":"10.1101\/cshperspect.a038240"},{"issue":"6","key":"991_CR7","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3322\/caac.21785","volume":"73","author":"Z Megyesfalvi","year":"2023","unstructured":"Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clinicians. 2023;73(6):620\u201352. https:\/\/doi.org\/10.3322\/caac.21785.","journal-title":"CA Cancer J Clinicians"},{"key":"991_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.20517\/cdr.2024.154","volume":"7","author":"Y Nie","year":"2024","unstructured":"Nie Y, Schalper KA, Chiang A. Mechanisms of immunotherapy resistance in small cell lung cancer. Cancer Drug Resist. 2024;7:55. https:\/\/doi.org\/10.20517\/cdr.2024.154.","journal-title":"Cancer Drug Resist"},{"issue":"3","key":"991_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(3):346\u201360.e7. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.014.","journal-title":"Cancer Cell"},{"issue":"13\u201314","key":"991_CR10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1101\/gad.314815.118","volume":"32","author":"YH Huang","year":"2018","unstructured":"Huang YH, Klingbeil O, He XY, Wu S, Arun G, Lu B, et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev. 2018;32(13\u201314):915\u201328. https:\/\/doi.org\/10.1101\/gad.314815.118.","journal-title":"Genes Dev"},{"issue":"5","key":"991_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19(5):289\u201397. https:\/\/doi.org\/10.1038\/s41568-019-0133-9.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"991_CR12","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","volume":"15","author":"MK Baine","year":"2020","unstructured":"Baine MK, Hsieh MS, Lai WV, Egger J, Jungbluth AA, Daneshbod Y, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol. 2020;15(12):1823\u201335. https:\/\/doi.org\/10.1016\/j.jtho.2020.09.009.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"991_CR13","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3390\/ijms26031293","volume":"26","author":"A I\u00f1a\u00f1ez","year":"2025","unstructured":"I\u00f1a\u00f1ez A, Del Rey-Vergara R, Quimis F, Rocha P, Galindo M, Men\u00e9ndez S, et al. The potential of single-transcription factor gene expression by RT-qPCR for subtyping small cell lung cancer. IJMS. 2025;26(3):1293. https:\/\/doi.org\/10.3390\/ijms26031293.","journal-title":"IJMS"},{"issue":"9","key":"991_CR14","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-23-2360","volume":"30","author":"J Ng","year":"2024","unstructured":"Ng J, Cai L, Girard L, Prall OWJ, Rajan N, Khoo C, et al. Molecular and pathologic characterization of YAP1-expressing small cell lung cancer cell lines leads to reclassification as SMARCA4-deficient malignancies. Clin Cancer Res. 2024;30(9):1846\u201358. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2360.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"991_CR15","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.3390\/diagnostics14232660","volume":"14","author":"A Vigdorovits","year":"2024","unstructured":"Vigdorovits A, Olteanu G-E, Pascalau A-V, Pirlog R, Berindan-Neagoe I, Pop O-L, et al. Novel immunohistochemical profiling of small-cell lung cancer: correlations between tumor subtypes and immune microenvironment. Diagnostics. 2024;14(23):2660. https:\/\/doi.org\/10.3390\/diagnostics14232660.","journal-title":"Diagnostics"},{"issue":"7654","key":"991_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature22323","volume":"545","author":"JS Lim","year":"2017","unstructured":"Lim JS, Ibaseta A, Fischer MM, Cancilla B, O\u2019Young G, Cristea S, et al. Intratumoural heterogeneity generated by notch signalling promotes small-cell lung cancer. Nature. 2017;545(7654):360\u201364. https:\/\/doi.org\/10.1038\/nature22323.","journal-title":"Nature"},{"issue":"5","key":"991_CR17","doi-asserted-by":"publisher","first-page":"115603","DOI":"10.1016\/j.celrep.2025.115603","volume":"44","author":"A Catozzi","year":"2025","unstructured":"Catozzi A, Peiris Pag\u00e8s M, Humphrey S, Revill M, Morgan D, Roebuck J, et al. Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancer. Cell Rep. 2025;44(5):115603. https:\/\/doi.org\/10.1016\/j.celrep.2025.115603.","journal-title":"Cell Rep"},{"issue":"12","key":"991_CR18","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.21037\/tlcr-23-505","volume":"12","author":"H Popper","year":"2023","unstructured":"Popper H, Brcic L, Eidenhammer S. Does subtyping of high-grade pulmonary neuroendocrine carcinomas have an impact on therapy selection? Transl Lung Cancer Res. 2023;12(12):2412\u201326. https:\/\/doi.org\/10.21037\/tlcr-23-505.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"991_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41698-025-00860-6","volume":"9","author":"H Watanabe","year":"2025","unstructured":"Watanabe H, Sato T, Yamada T, Kudo N, Sanada M, Matsuo A, et al. Lethal co-expression intolerance underlies the mutually exclusive expression of ASCL1 and NEUROD1 in SCLC cells. npj Precis. Onc. 2025;9(1):74. https:\/\/doi.org\/10.1038\/s41698-025-00860-6.","journal-title":"npj Precis. Onc"},{"key":"991_CR20","doi-asserted-by":"publisher","unstructured":"Wooten DJ, Groves SM, Tyson DR, Liu Q, Lim JS, Albert R, et al. Systems-level network modeling of Small cell lung cancer subtypes identifies master regulators and destabilizers. PLoS Comput Biol. 2019;15(10):e1007343. https:\/\/doi.org\/10.1371\/journal.pcbi.1007343.","DOI":"10.1371\/journal.pcbi.1007343"},{"issue":"1","key":"991_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","volume":"38","author":"AS Ireland","year":"2020","unstructured":"Ireland AS, Micinski AM, Kastner DW, Guo B, Wait SJ, Spainhower KB, et al. MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell. 2020;38(1):60\u201378.e12. https:\/\/doi.org\/10.1016\/j.ccell.2020.05.001.","journal-title":"Cancer Cell"},{"issue":"6","key":"991_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/gm62","volume":"1","author":"A Shlien","year":"2009","unstructured":"Shlien A, Malkin D. Copy number variations and cancer. Genome Med. 2009;1(6):62. https:\/\/doi.org\/10.1186\/gm62.","journal-title":"Genome Med"},{"issue":"3","key":"991_CR23","doi-asserted-by":"publisher","first-page":"108296","DOI":"10.1016\/j.celrep.2020.108296","volume":"33","author":"C Tlemsani","year":"2020","unstructured":"Tlemsani C, Pongor L, Elloumi F, Girard L, Huffman KE, Roper N, et al. SCLC-CellMiner: a resource for small cell lung cancer cell line genomics and pharmacology based on genomic signatures. Cell Rep. 2020;33(3):108296. https:\/\/doi.org\/10.1016\/j.celrep.2020.108296.","journal-title":"Cell Rep"},{"issue":"12","key":"991_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0349-5","volume":"51","author":"KB Kim","year":"2019","unstructured":"Kim KB, Dunn CT, Park KS. Recent progress in mapping the emerging landscape of the small-cell lung cancer genome. Exp Mol Med. 2019;51(12):1\u201313. https:\/\/doi.org\/10.1038\/s12276-019-0349-5.","journal-title":"Exp Mol Med"},{"issue":"3","key":"991_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.lungcan.2013.05.022","volume":"81","author":"G Toyokawa","year":"2013","unstructured":"Toyokawa G, Takenoyama M, Taguchi K, Toyozawa R, Inamasu E, Kojo M, et al. An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene. Lung Cancer. 2013;81(3):487\u201390. https:\/\/doi.org\/10.1016\/j.lungcan.2013.05.022.","journal-title":"Lung Cancer"},{"key":"991_CR26","doi-asserted-by":"publisher","first-page":"108497","DOI":"10.1016\/j.lungcan.2025.108497","volume":"202","author":"G Jaber","year":"2025","unstructured":"Jaber G, Raffoul C, Diab T, Sinno S, Barakat Z, Assi HI. ALK-EML4 fusion in Small cell lung cancer: clinical and molecular insights from a rare case. Lung Cancer. 2025;202:108497. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108497.","journal-title":"Lung Cancer"},{"issue":"1","key":"991_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41698-020-0127-9","volume":"4","author":"JJ Lin","year":"2020","unstructured":"Lin JJ, Langenbucher A, Gupta P, Yoda S, Fetter IJ, Rooney M, et al. Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. npj Precis. Onc. 2020;4(1):21. https:\/\/doi.org\/10.1038\/s41698-020-0127-9.","journal-title":"npj Precis. Onc"},{"issue":"1","key":"991_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cllc.2022.10.005","volume":"24","author":"A Gazeu","year":"2023","unstructured":"Gazeu A, Aubert M, Pissaloux D, Lantuejoul S, P\u00e9rol M, Ikhlef N, et al. Small-cell lung cancer transformation as a mechanism of resistance to pralsetinib in RET-Rearranged lung adenocarcinoma: a case report. Clin Lung Cancer. 2023;24(1):72\u201375. https:\/\/doi.org\/10.1016\/j.cllc.2022.10.005.","journal-title":"Clin Lung Cancer"},{"key":"991_CR29","doi-asserted-by":"publisher","unstructured":"Dimou A, Lo YC, Merrell KW, Halling KC, Mansfield AS. Small cell transformation in a patient with RET fusion\u2013positive lung adenocarcinoma on pralsetinib. JCO Precis Oncol. 2022;6(6):e2200478. https:\/\/doi.org\/10.1200\/PO.22.00478.","DOI":"10.1200\/PO.22.00478"},{"issue":"7563","key":"991_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George J, Lim JS, Jang SJ, Cun Y, Ozreti\u0107 L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47\u201353. https:\/\/doi.org\/10.1038\/nature14664.","journal-title":"Nature"},{"issue":"Suppl 4","key":"991_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/sonc.2001.25738","volume":"28","author":"II Wistuba","year":"2001","unstructured":"Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol. 2001;28(Suppl 4):3\u201313. https:\/\/doi.org\/10.1053\/sonc.2001.25738.","journal-title":"Semin Oncol"},{"issue":"17","key":"991_CR32","doi-asserted-by":"publisher","first-page":"13082","DOI":"10.3390\/ijms241713082","volume":"24","author":"V Neely","year":"2023","unstructured":"Neely V, Manchikalapudi A, Nguyen K, Dalton K, Hu B, Koblinski JE, et al. Targeting oncogenic mutant p53 and BCL-2 for small cell lung cancer treatment. IJMS. 2023;24(17):13082. https:\/\/doi.org\/10.3390\/ijms241713082.","journal-title":"IJMS"},{"issue":"21","key":"991_CR33","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1158\/1078-0432.CCR-22-1115","volume":"28","author":"CA Febres-Aldana","year":"2022","unstructured":"Febres-Aldana CA, Chang JC, Ptashkin R, Wang Y, Gedvilaite E, Baine MK, et al. Rb tumor suppressor in Small cell lung cancer: combined genomic and IHC analysis with a description of a distinct Rb-proficient subset. Clin Cancer Res. 2022;28(21):4702\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1115.","journal-title":"Clin Cancer Res"},{"issue":"23\u201324","key":"991_CR34","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1101\/gad.328336.119","volume":"33","author":"MG Oser","year":"2019","unstructured":"Oser MG, Niederst MJ, Sequist LV, Engelman JA. The KDM5A\/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes Dev. 2019;33(23\u201324):1718\u201338. https:\/\/doi.org\/10.1101\/gad.328336.119.","journal-title":"Genes Dev"},{"issue":"9","key":"991_CR35","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1097\/JTO.0000000000000250","volume":"9","author":"S Umemura","year":"2014","unstructured":"Umemura S, Mimaki S, Makinoshima H, Tada S, Ishii G, Ohmatsu H, et al. Therapeutic priority of the PI3K\/AKT\/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol. 2014;9(9):1324\u201331. https:\/\/doi.org\/10.1097\/JTO.0000000000000250.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"991_CR36","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jtho.2016.12.011","volume":"12","author":"A Augert","year":"2017","unstructured":"Augert A, Zhang Q, Bates B, Cui M, Wang X, Wildey G, et al. Small cell lung cancer exhibits frequent inactivating mutations in the histone methyltransferase KMT2D\/MLL2: CALGB 151111 (alliance). J Thorac Oncol. 2017;12(4):704\u201313. https:\/\/doi.org\/10.1016\/j.jtho.2016.12.011.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"991_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3349\/ymj.2002.43.2.145","volume":"43","author":"ES Cho","year":"2002","unstructured":"Cho ES, Kim YH, Kim SK, Lee J, Lee S, et al., Kim H. Identification of tumor suppressor loci on the long arm of chromosome 4 in primary small cell lung cancers. Yonsei Med J. 2002;43(2):145\u201351. https:\/\/doi.org\/10.3349\/ymj.2002.43.2.145.","journal-title":"Yonsei Med J"},{"issue":"4","key":"991_CR38","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/sj.onc.1201956","volume":"17","author":"A Yokomizo","year":"1998","unstructured":"Yokomizo A, Tindall DJ, Drabkin H, Gemmill R, Franklin W, Yang P, et al. PTEN\/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene. 1998;17(4):475\u201379. https:\/\/doi.org\/10.1038\/sj.onc.1201956.","journal-title":"Oncogene"},{"issue":"10","key":"991_CR39","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/ng.2405","volume":"44","author":"CM Rudin","year":"2012","unstructured":"Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44(10):1111\u201316. https:\/\/doi.org\/10.1038\/ng.2405.","journal-title":"Nat Genet"},{"issue":"13","key":"991_CR40","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/sj.onc.1202073","volume":"17","author":"SK Kim","year":"1998","unstructured":"Kim SK, Tamura K, Yokomizo A, Nakagawa K, Kohno T, Yokota J, et al. Identification of two distinct tumor-suppressor loci on the long arm of chromosome 10 in small cell lung cancer. Oncogene. 1998;17(13):1749\u201353. https:\/\/doi.org\/10.1038\/sj.onc.1202073.","journal-title":"Oncogene"},{"issue":"1","key":"991_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0002-9440(10)64172-7","volume":"161","author":"S Yokoi","year":"2002","unstructured":"Yokoi S, Yasui K, Saito-Ohara F, Koshikawa K, Iizasa T, Fujisawa T, et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol. 2002;161(1):207\u201316. https:\/\/doi.org\/10.1016\/S0002-9440(10)64172-7.","journal-title":"Am J Pathol"},{"issue":"10","key":"991_CR42","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ng.2396","volume":"44","author":"M Peifer","year":"2012","unstructured":"Peifer M, Fern\u00e1ndez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44(10):1104\u201310. https:\/\/doi.org\/10.1038\/ng.2396.","journal-title":"Nat Genet"},{"issue":"9","key":"991_CR43","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/gcc.22076","volume":"52","author":"R Iwakawa","year":"2013","unstructured":"Iwakawa R, Takenaka M, Kohno T, Shimada Y, Totoki Y, Shibata T, et al. Genome-wide identification of genes with amplification and\/or fusion in small cell lung cancer. Genes Chromosomes Cancer. 2013;52(9):802\u201316. https:\/\/doi.org\/10.1002\/gcc.22076.","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"991_CR44","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/2159-8290.CD-22-0796","volume":"13","author":"LS Pongor","year":"2023","unstructured":"Pongor LS, Schultz CW, Rinaldi L, Wangsa D, Redon CE, Takahashi N, et al. Extrachromosomal DNA amplification contributes to small cell lung cancer heterogeneity and is associated with worse outcomes. Cancer DiscovCancer Discov. 2023;13(4):928\u201349. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0796.","journal-title":"Cancer DiscovCancer Discov"},{"key":"991_CR45","doi-asserted-by":"publisher","unstructured":"Repetto M, Richards AL, Chen MF, Selenica P, Suman S, Zhu Y, et al. The genomic landscape of MYC -, MYCL -, and MYCN -Amplified solid tumors. Clin Cancer Res. 2026;OF1\u201312. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-4102.","DOI":"10.1158\/1078-0432.CCR-25-4102"},{"key":"991_CR46","doi-asserted-by":"publisher","first-page":"114248","DOI":"10.1016\/j.biopha.2023.114248","volume":"159","author":"H Zhang","year":"2023","unstructured":"Zhang H, Li Y, Wang X, Chen Y, Liu J, Zhao Q, et al. Targeting the notch signaling pathway and the notch ligand, DLL3, in small cell lung cancer. Biomed Pharmacother. 2023;159:114248. https:\/\/doi.org\/10.1016\/j.biopha.2023.114248.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"991_CR47","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s100380200048","volume":"47","author":"K Tamura","year":"2002","unstructured":"Tamura K, Kim SK, Yokomizo A, Nakagawa K, Kohno T, Yokota J, et al. Homozygous deletion on the chromosomal region 5q12.3 in human lines of small-cell lung cancers. J Hum Genet. 2002;47(7):348\u201354. https:\/\/doi.org\/10.1007\/s100380200048.","journal-title":"J Hum Genet"},{"issue":"12","key":"991_CR48","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/s41374-020-00479-0","volume":"100","author":"Y Tenjin","year":"2020","unstructured":"Tenjin Y, Matsuura K, Kudoh S, Usuki S, Yamada T, Matsuo A, et al. Distinct transcriptional programs of SOX2 in different types of small cell lung cancers. Lab Investigation. 2020;100(12):1575\u201388. https:\/\/doi.org\/10.1038\/s41374-020-00479-0.","journal-title":"Lab Investigation"},{"issue":"29","key":"991_CR49","doi-asserted-by":"publisher","first-page":"13040","DOI":"10.1073\/pnas.1008132107","volume":"107","author":"J Voortman","year":"2010","unstructured":"Voortman J, Lee JH, Killian JK, Suuriniemi M, Wang Y, Lucchi M, et al. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci USA. 2010;107(29):13040\u201345. https:\/\/doi.org\/10.1073\/pnas.1008132107.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"991_CR50","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.cell.2026.03.011","volume":"189","author":"IT-L Wong","year":"2026","unstructured":"Wong IT-L, Bailey C, Wu S, Henssen AG, Cravatt BF, Chen ZJ, et al. A recipe for chaos: extrachromosomal DNA and the hallmarks of cancer. Cell. 2026;189(8):2307\u201321. https:\/\/doi.org\/10.1016\/j.cell.2026.03.011.","journal-title":"Cell"},{"issue":"14","key":"991_CR51","doi-asserted-by":"publisher","first-page":"9131","DOI":"10.1093\/nar\/gku590","volume":"42","author":"A L\u2019Abbate","year":"2014","unstructured":"L\u2019Abbate A, Macchia G, D\u2019Addabbo P, Lonoce A, Tolomeo D, Trombetta D, et al. Genomic organization and evolution of double minutes\/homogeneously staining regions with MYC amplification in human cancer. Nucleic Acids Res. 2014;42(14):9131\u201345. https:\/\/doi.org\/10.1093\/nar\/gku590.","journal-title":"Nucleic Acids Res"},{"key":"991_CR52","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1073\/pnas.0510779103","volume":"103","author":"YH Kim","year":"2006","unstructured":"Kim YH, Girard L, Giacomini CP, Wang P, Hernandez-Boussard T, Tibshirani R, et al. Combined microarray analysis reveals altered apoptotic balance in SCLC. Proc Natl Acad Sci U S A. 2006;103:3771\u201376. https:\/\/doi.org\/10.1073\/pnas.0510779103.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"991_CR53","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.ccm.2011.08.003","volume":"32","author":"JE Larsen","year":"2011","unstructured":"Larsen JE, Minna JD. Molecular biology of lung cancer: clinical implications. Clinics Chest Med. 2011;32(4):703\u201340. https:\/\/doi.org\/10.1016\/j.ccm.2011.08.003.","journal-title":"Clinics Chest Med"},{"issue":"4","key":"991_CR54","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1128\/mcb.8.4.1525-1533.1988","volume":"8","author":"SM Carroll","year":"1988","unstructured":"Carroll SM, DeRose ML, Gaudray P, Moore CM, Needham-Vandevanter DR, Von Hoff DD, et al. Double minute chromosomes can be produced from precursors derived from a chromosomal deletion. Mol Cell Biol. 1988;8(4):1525\u201333. https:\/\/doi.org\/10.1128\/mcb.8.4.1525-1533.1988.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"991_CR55","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/hmg\/ddl010","volume":"15","author":"CT Storlazzi","year":"2006","unstructured":"Storlazzi CT, Fioretos T, Surace C, Lonoce A, Mastrorilli A, Strombeck B, et al. MYC-containing double minutes in hematologic malignancies: evidence in favor of the episome model and exclusion of MYC as the target gene. Hum Mol Genet. 2006;15(6):933\u201342. https:\/\/doi.org\/10.1093\/hmg\/ddl010.","journal-title":"Hum Mol Genet"},{"issue":"9","key":"991_CR56","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1101\/gr.106252.110","volume":"20","author":"CT Storlazzi","year":"2010","unstructured":"Storlazzi CT, Lonoce A, Guastadisegni MC, Trombetta D, D\u2019Addabbo P, Daniele G, et al. Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. Genome Res. 2010;20(9):1198\u2013206. https:\/\/doi.org\/10.1101\/gr.106252.110.","journal-title":"Genome Res"},{"issue":"10","key":"991_CR57","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/s41375-018-0033-0","volume":"32","author":"A L\u2032abbate","year":"2018","unstructured":"L\u2032abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, et al. MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences. Leukemia. 2018;32(10):2152\u201366. https:\/\/doi.org\/10.1038\/s41375-018-0033-0.","journal-title":"Leukemia"},{"issue":"7784","key":"991_CR58","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41586-019-1763-5","volume":"575","author":"S Wu","year":"2019","unstructured":"Wu S, Turner KM, Nguyen N, Raviram R, Erb M, Santini J, et al. Circular ecDNA promotes accessible chromatin and high oncogene expression. Nature. 2019;575(7784):699\u2013703. https:\/\/doi.org\/10.1038\/s41586-019-1763-5.","journal-title":"Nature"},{"issue":"9","key":"991_CR59","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s41588-020-0678-2","volume":"52","author":"H Kim","year":"2020","unstructured":"Kim H, Nguyen NP, Turner K, Wu S, Gujar AD, Luebeck J, et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat Genet. 2020;52(9):891\u201397. https:\/\/doi.org\/10.1038\/s41588-020-0678-2.","journal-title":"Nat Genet"},{"issue":"4","key":"991_CR60","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41588-019-0360-8","volume":"51","author":"P Ly","year":"2019","unstructured":"Ly P, Brunner SF, Shoshani O, Kim DH, Lan W, Pyntikova T, et al. Chromosome segregation errors generate a diverse spectrum of simple and complex genomic rearrangements. Nat Genet. 2019;51(4):705\u201315. https:\/\/doi.org\/10.1038\/s41588-019-0360-8.","journal-title":"Nat Genet"},{"issue":"8095","key":"991_CR61","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41586-025-09764-8","volume":"649","author":"V Sankar","year":"2026","unstructured":"Sankar V, Hung KL, Gnanasekar A, Wong IT-L, Shi Q, Kraft KM, et al. Genetic elements promote retention of extrachromosomal DNA in cancer cells. Nature. 2026;649(8095):152\u201360. https:\/\/doi.org\/10.1038\/s41586-025-09764-8.","journal-title":"Nature"},{"issue":"6","key":"991_CR62","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/genes14061304","volume":"14","author":"A Arshadi","year":"2023","unstructured":"Arshadi A, Tolomeo D, Venuto S, Storlazzi CT. Advancements in focal amplification detection in tumor\/liquid biopsies and emerging clinical applications. Genes (Basel). 2023;14(6):1304. https:\/\/doi.org\/10.3390\/genes14061304.","journal-title":"Genes (Basel)"},{"issue":"13","key":"991_CR63","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1073\/pnas.85.13.4804","volume":"85","author":"DD Von Hoff","year":"1988","unstructured":"Von Hoff DD, Needham-VanDevanter DR, Yucel J, Windle BE, Wahl GM. Amplified human MYC oncogenes localized to replicating submicroscopic circular DNA molecules. Proc Natl Acad Sci USA. 1988;85(13):4804\u201308. https:\/\/doi.org\/10.1073\/pnas.85.13.4804.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7890","key":"991_CR64","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41586-021-04116-8","volume":"600","author":"KL Hung","year":"2021","unstructured":"Hung KL, Yost KE, Xie L, Shi Q, Helmsauer K, Luebeck J, et al. ecDNA hubs drive cooperative intermolecular oncogene expression. Nature. 2021;600(7890):731\u201336. https:\/\/doi.org\/10.1038\/s41586-021-04116-8.","journal-title":"Nature"},{"issue":"1","key":"991_CR65","doi-asserted-by":"publisher","first-page":"5823","DOI":"10.1038\/s41467-020-19452-y","volume":"11","author":"K Helmsauer","year":"2020","unstructured":"Helmsauer K, Valieva ME, Ali S, Chamorro Gonz\u00e1lez R, Sch\u00f6pflin R, R\u00f6efzaad C, et al. Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma. Nat Commun. 2020;11(1):5823. https:\/\/doi.org\/10.1038\/s41467-020-19452-y.","journal-title":"Nat Commun"},{"issue":"7643","key":"991_CR66","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nature21356","volume":"543","author":"KM Turner","year":"2017","unstructured":"Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. 2017;543(7643):122\u201325. https:\/\/doi.org\/10.1038\/nature21356.","journal-title":"Nature"},{"issue":"12","key":"991_CR67","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/2159-8290.CD-21-0441","volume":"11","author":"M Ciampricotti","year":"2021","unstructured":"Ciampricotti M, Karakousi T, Richards AL, Quintanal-Villalonga \u00c0, Karatza A, Caeser R, et al. Rlf\u2013mycl gene fusion drives tumorigenesis and metastasis in a mouse Model of small cell lung cancer. Cancer DiscovCancer Discov. 2021;11(12):3214\u201329. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0441.","journal-title":"Cancer DiscovCancer Discov"},{"issue":"6","key":"991_CR68","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ng.128","volume":"40","author":"PJ Campbell","year":"2008","unstructured":"Campbell PJ, Stephens PJ, Pleasance ED, O\u2019Meara S, Li H, Santarius T, et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet. 2008;40(6):722\u201329. https:\/\/doi.org\/10.1038\/ng.128.","journal-title":"Nat Genet"},{"issue":"7278","key":"991_CR69","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nature08629","volume":"463","author":"ED Pleasance","year":"2010","unstructured":"Pleasance ED, Stephens PJ, O\u2019Meara S, McBride DJ, Meynert A, Jones D, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010;463(7278):184\u201390. https:\/\/doi.org\/10.1038\/nature08629.","journal-title":"Nature"},{"issue":"9","key":"991_CR70","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.trecan.2016.07.006","volume":"2","author":"Y Jia","year":"2016","unstructured":"Jia Y, Xie Z, Li H. Intergenically spliced chimeric RNAs in cancer. Trends Cancer. 2016;2(9):475\u201384. https:\/\/doi.org\/10.1016\/j.trecan.2016.07.006.","journal-title":"Trends Cancer"},{"key":"991_CR71","doi-asserted-by":"publisher","unstructured":"Dorney R, Dhungel BP, Rasko JEJ, Hebbard L, Schmitz U. Recent advances in cancer fusion transcript detection. Briefings Bioinf. 2023;24(1):bbac519. https:\/\/doi.org\/10.1093\/bib\/bbac519.","DOI":"10.1093\/bib\/bbac519"},{"issue":"19","key":"991_CR72","doi-asserted-by":"publisher","first-page":"4954","DOI":"10.1158\/0008-5472.CAN-12-0213","volume":"72","author":"H Nagoshi","year":"2012","unstructured":"Nagoshi H, Taki T, Hanamura I, Nitta M, Otsuki T, Nishida K, et al. Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality. Cancer Res. 2012;72(19):4954\u201362. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0213.","journal-title":"Cancer Res"},{"issue":"7409","key":"991_CR73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature11327","volume":"488","author":"PA Northcott","year":"2012","unstructured":"Northcott PA, Shih DJH, Peacock J, Garzia L, Morrissy AS, Zichner T, et al. Subgroup-specific structural variation across 1, 000 medulloblastoma genomes. Nature. 2012;488(7409):49\u201356. https:\/\/doi.org\/10.1038\/nature11327.","journal-title":"Nature"},{"issue":"47","key":"991_CR74","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1038\/onc.2013.490","volume":"33","author":"HP Kim","year":"2014","unstructured":"Kim HP, Cho GA, Han SW, Shin JY, Jeong EG, Song SH, et al. Novel fusion transcripts in human gastric cancer revealed by transcriptome analysis. Oncogene. 2014;33(47):5434\u201341. https:\/\/doi.org\/10.1038\/onc.2013.490.","journal-title":"Oncogene"},{"issue":"5","key":"991_CR75","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41568-019-0128-6","volume":"19","author":"RGW Verhaak","year":"2019","unstructured":"Verhaak RGW, Bafna V, Mischel PS. Extrachromosomal oncogene amplification in tumour pathogenesis and evolution. Nat Rev Cancer. 2019;19(5):283\u201388. https:\/\/doi.org\/10.1038\/s41568-019-0128-6.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"991_CR76","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.cell.2025.12.009","volume":"189","author":"H Yi","year":"2026","unstructured":"Yi H, Zhang S, Swinderman J, Wang Y, Kanakaveti V, Hung KL, et al. ecDNA-borne structural variants drive oncogenic fusion transcript amplification. Cell. 2026;189(3):906\u201321.e20. https:\/\/doi.org\/10.1016\/j.cell.2025.12.009.","journal-title":"Cell"},{"issue":"7","key":"991_CR77","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/gcc.23121","volume":"62","author":"D Tolomeo","year":"2023","unstructured":"Tolomeo D, Traversa D, Venuto S, Ebbesen KK, Garc\u00eda Rodr\u00edguez JL, Tamma G, et al. circPVT1 and PVT1\/AKT3 show a role in cell proliferation, apoptosis, and tumor subtype-definition in small cell lung cancer. Genes Chromosomes Cancer. 2023;62(7):377\u201391. https:\/\/doi.org\/10.1002\/gcc.23121.","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"991_CR78","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/2159-8290.CD-23-0656","volume":"14","author":"S Pal Choudhuri","year":"2024","unstructured":"Pal Choudhuri S, Girard L, Lim JYS, Wise JF, Freitas B, Yang D, et al. Acquired cross-resistance in small cell lung cancer due to extrachromosomal DNA amplification of MYC paralogs. Cancer DiscovCancer Discov. 2024;14(5):804\u201327. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0656.","journal-title":"Cancer DiscovCancer Discov"},{"issue":"8005","key":"991_CR79","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41586-024-07177-7","volume":"627","author":"J George","year":"2024","unstructured":"George J, Maas L, Abedpour N, Cartolano M, Kaiser L, Fischer RN, et al. Evolutionary trajectories of small cell lung cancer under therapy. Nature. 2024;627(8005):880\u201389. https:\/\/doi.org\/10.1038\/s41586-024-07177-7.","journal-title":"Nature"},{"issue":"6","key":"991_CR80","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1158\/2159-8290.CD-25-0230","volume":"15","author":"NE Weiser","year":"2025","unstructured":"Weiser NE, Watkins TBK, Chang HY, Mischel PS. A Guide to extrachromosomal DNA: Cancer\u2019s dynamic circular genome. Cancer DiscovCancer Discov. 2025;15(6):1105\u201314. https:\/\/doi.org\/10.1158\/2159-8290.CD-25-0230.","journal-title":"Cancer DiscovCancer Discov"},{"issue":"10","key":"991_CR81","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.trecan.2024.07.008","volume":"10","author":"E Redin","year":"2024","unstructured":"Redin E, Quintanal-Villalonga \u00c1, Rudin CM. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. Trends Cancer. 2024;10(10):935\u201346. https:\/\/doi.org\/10.1016\/j.trecan.2024.07.008.","journal-title":"Trends Cancer"},{"issue":"1","key":"991_CR82","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1038\/s41467-022-29517-9","volume":"13","author":"D Lissa","year":"2022","unstructured":"Lissa D, Takahashi N, Desai P, Manukyan I, Schultz CW, Rajapakse V, et al. Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models. Nat Commun. 2022;13(1):2023. https:\/\/doi.org\/10.1038\/s41467-022-29517-9.","journal-title":"Nat Commun"},{"issue":"41","key":"991_CR83","doi-asserted-by":"publisher","first-page":"14788","DOI":"10.1073\/pnas.1410419111","volume":"111","author":"A Augustyn","year":"2014","unstructured":"Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci USA. 2014;111(41):14788\u201393. https:\/\/doi.org\/10.1073\/pnas.1410419111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"991_CR84","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","volume":"29","author":"L Gandhi","year":"2011","unstructured":"Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, et al. Phase I study of navitoclax (ABT-263), a novel bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. JCO. 2011;29(7):909\u201316. https:\/\/doi.org\/10.1200\/JCO.2010.31.6208.","journal-title":"JCO"},{"key":"991_CR85","doi-asserted-by":"publisher","unstructured":"Augert A, Eastwood E, Ibrahim AH, Wu N, Grunblatt E, Basom R, et al. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Sci Signal. 2019;12(567):eaau2922. https:\/\/doi.org\/10.1126\/scisignal.aau2922.","DOI":"10.1126\/scisignal.aau2922"},{"issue":"17","key":"991_CR86","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1158\/0008-5472.CAN-16-3502","volume":"77","author":"S Takagi","year":"2017","unstructured":"Takagi S, Ishikawa Y, Mizutani A, Iwasaki S, Matsumoto S, Kamada Y, et al. LSD1 inhibitor T-3775440 inhibits SCLC cell proliferation by disrupting LSD1 interactions with SNAG Domain proteins INSM1 and GFI1B. Cancer Res. 2017;77(17):4652\u201362. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-3502.","journal-title":"Cancer Res"},{"issue":"1","key":"991_CR87","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-024-01953-9","volume":"23","author":"A Solta","year":"2024","unstructured":"Solta A, Ernhofer B, Boettiger K, Megyesfalvi Z, Heeke S, Hoda MA, et al. Small cells \u2013 big issues: biological implications and preclinical advancements in small cell lung cancer. Mol Cancer. 2024;23(1):41. https:\/\/doi.org\/10.1186\/s12943-024-01953-9.","journal-title":"Mol Cancer"},{"key":"991_CR88","doi-asserted-by":"publisher","unstructured":"Navarro Mendivil AF, Gutierrez S, Maes T, Bullock R, Ropacki M, Buesa C. CLEPSIDRA trial: a pilot, biomarker-guided study to assess safety, tolerability, dose finding and efficacy of iadademstat in combination with platinum-etoposide in patients with relapsed, extensive-stage small cell lung cancer. Ann Oncol. 2019;30(Suppl 5):v717. https:\/\/doi.org\/10.1093\/annonc\/mdz264.015.","DOI":"10.1093\/annonc\/mdz264.015"},{"key":"991_CR89","doi-asserted-by":"publisher","unstructured":"Navarro A, Guti\u00e9rrez S, Bullock R, Buesa C, et al. 1806P final safety and efficacy data from CLEPSIDRA trial in 2L ED-SCLC. Ann Oncol. 2020;31(1044):S1044. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.1567.","DOI":"10.1016\/j.annonc.2020.08.1567"},{"issue":"2","key":"991_CR90","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ydbio.2009.01.007","volume":"328","author":"RM Henke","year":"2009","unstructured":"Henke RM, Meredith DM, Borromeo MD, Savage TK, Johnson JE. Ascl1 and Neurog2 form novel complexes and regulate delta-like3 (Dll3) expression in the neural tube. Dev Biol. 2009;328(2):529\u201340. https:\/\/doi.org\/10.1016\/j.ydbio.2009.01.007.","journal-title":"Dev Biol"},{"issue":"1","key":"991_CR91","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","volume":"18","author":"CM Rudin","year":"2017","unstructured":"Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. The Lancet Oncol. 2017;18(1):42\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(16)30565-4.","journal-title":"The Lancet Oncol"},{"key":"991_CR92","doi-asserted-by":"publisher","unstructured":"Furuta M, Sakakibara-Konishi J, Kikuchi H, Yokouchi H, Nishihara H, Minemura H, et al. Analysis of DLL3 and ASCL1 in surgically resected small cell lung cancer (HOT1702). Oncologist. 2019;24(11):e1172\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2018-0676.","DOI":"10.1634\/theoncologist.2018-0676"},{"issue":"9","key":"991_CR93","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","volume":"16","author":"F Blackhall","year":"2021","unstructured":"Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study. J Thorac Oncol. 2021;16(9):1547\u201358. https:\/\/doi.org\/10.1016\/j.jtho.2021.02.009.","journal-title":"J Thorac Oncol"},{"issue":"16","key":"991_CR94","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study. JCO. 2023;41(16):2893\u2013903. https:\/\/doi.org\/10.1200\/JCO.22.02823.","journal-title":"JCO"},{"issue":"22","key":"991_CR95","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. Tarlatamab for patients with Previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2307980.","journal-title":"N Engl J Med"},{"issue":"4","key":"991_CR96","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","volume":"393","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC, Demirci U, Baka S, G\u00fcm\u00fc\u015f M, et al. Tarlatamab in Small-cell lung cancer after platinum-based chemotherapy. N Engl J Med. 2025;393(4):349\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2502099.","journal-title":"N Engl J Med"},{"issue":"10","key":"991_CR97","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","volume":"26","author":"KG Paulson","year":"2025","unstructured":"Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, H\u00e4fliger S, et al. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLlphi-303): a multicentre, non-randomised, phase 1b study. The Lancet Oncol. 2025;26(10):1300\u201311. https:\/\/doi.org\/10.1016\/S1470-2045(25)00480-2.","journal-title":"The Lancet Oncol"},{"issue":"5","key":"991_CR98","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1158\/2159-8290.CD-25-1483","volume":"16","author":"A Mishra","year":"2026","unstructured":"Mishra A, Meador CB, Kikkeri K, Cunneely Q, Lin M, Carmona-LaSalle TJ, et al. Circulating tumor cells predict response to the DLL3-targeting bispecific antibody tarlatamab. Cancer DiscovCancer Discov. 2026;16(5):911\u201330. https:\/\/doi.org\/10.1158\/2159-8290.CD-25-1483.","journal-title":"Cancer DiscovCancer Discov"},{"issue":"2","key":"991_CR99","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","volume":"31","author":"G Mollaoglu","year":"2017","unstructured":"Mollaoglu G, Guthrie MR, B\u00f6hm S, Br\u00e4gelmann J, Can I, Ballieu PM, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition. Cancer Cell. 2017;31(2):270\u201385. https:\/\/doi.org\/10.1016\/j.ccell.2016.12.005.","journal-title":"Cancer Cell"},{"issue":"10","key":"991_CR100","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1158\/1535-7163.MCT-16-0298","volume":"15","author":"BA Helfrich","year":"2016","unstructured":"Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, et al. Barasertib (AZD1152), a small molecule aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo. Mol Cancer Ther. 2016;15(10):2314\u201322. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0298.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"991_CR101","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3390\/molecules30081731","volume":"30","author":"D Huang","year":"2025","unstructured":"Huang D, Wang J, Chen L, Jiang W, Inuzuka H, Simon DK, et al. Molecular subtypes and targeted therapeutic strategies in small cell lung cancer: advances, challenges, and future perspectives. Molecules. 2025;30(8):1731. https:\/\/doi.org\/10.3390\/molecules30081731.","journal-title":"Molecules"},{"issue":"16","key":"991_CR102","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1158\/1078-0432.CCR-23-0375","volume":"29","author":"K Ramkumar","year":"2023","unstructured":"Ramkumar K, Tanimoto A, Della Corte CM, Stewart CA, Wang Q, Shen L, et al. Targeting BCL2 overcomes resistance and augments response to Aurora kinase B inhibition by AZD2811 in small cell lung cancer. Clin Cancer Res. 2023;29(16):3237\u201349. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0375.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"991_CR103","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jtho.2019.10.013","volume":"15","author":"TK Owonikoko","year":"2020","unstructured":"Owonikoko TK, Niu H, Nackaerts K, Csoszi T, Ostoros G, Mark Z, et al. Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: primary and correlative biomarker analyses. J Thorac Oncol. 2020;15(2):274\u201387. https:\/\/doi.org\/10.1016\/j.jtho.2019.10.013.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"991_CR104","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jtho.2019.05.004","volume":"14","author":"CM Gay","year":"2019","unstructured":"Gay CM, Byers LA. PARP inhibition combined with immune checkpoint blockade in SCLC: oasis in an immune desert or mirage? J Thorac Oncol. 2019;14(8):1323\u201326. https:\/\/doi.org\/10.1016\/j.jtho.2019.05.004.","journal-title":"J Thorac Oncol"},{"key":"991_CR105","doi-asserted-by":"publisher","unstructured":"Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, et al. Small cell lung cancer screen of oncology drugs, investigational agents, and gene and microRNA expression. JNCI J Natl Cancer Inst. 2016;108(10):djw122. https:\/\/doi.org\/10.1093\/jnci\/djw122.","DOI":"10.1093\/jnci\/djw122"},{"issue":"2","key":"991_CR106","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","volume":"23","author":"BH Lok","year":"2017","unstructured":"Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, et al. PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res. 2017;23(2):523\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1040.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"991_CR107","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","volume":"9","author":"AF Farago","year":"2019","unstructured":"Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer DiscovCancer Discov. 2019;9(10):1372\u201387. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0582.","journal-title":"Cancer DiscovCancer Discov"},{"issue":"3","key":"991_CR108","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jtho.2020.11.006","volume":"16","author":"TK Owonikoko","year":"2021","unstructured":"Owonikoko TK, Dwivedi B, Chen Z, Zhang C, Barwick B, Ernani V, et al. YAP1 expression in SCLC defines a distinct subtype with T-cell\u2013Inflamed phenotype. J Thorac Oncol. 2021;16(3):464\u201376. https:\/\/doi.org\/10.1016\/j.jtho.2020.11.006.","journal-title":"J Thorac Oncol"},{"key":"991_CR109","doi-asserted-by":"publisher","unstructured":"Jin Y, Zhao Q, Zhu W, Feng Y, Xiao T, Zhang P, et al. Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis. Natl Sci Rev. 2022;9(7):nwab232. https:\/\/doi.org\/10.1093\/nsr\/nwab232.","DOI":"10.1093\/nsr\/nwab232"},{"issue":"2","key":"991_CR110","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s13577-022-00669-6","volume":"35","author":"H Saito","year":"2022","unstructured":"Saito H, Tenjin Y, Yamada T, Kudoh S, Kudo N, Sanada M, et al. The role of YAP1 in small cell lung cancer. Hum Cell. 2022;35(2):628\u201338. https:\/\/doi.org\/10.1007\/s13577-022-00669-6.","journal-title":"Hum Cell"},{"issue":"12","key":"991_CR111","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jtho.2022.08.002","volume":"17","author":"E Redin","year":"2022","unstructured":"Redin E, Garrido-Martin EM, Valencia K, Redrado M, Solorzano JL, Carias R, et al. YES1 is a druggable oncogenic target in SCLC. J Thorac Oncol. 2022;17(12):1387\u2013403. https:\/\/doi.org\/10.1016\/j.jtho.2022.08.002.","journal-title":"J Thorac Oncol"},{"key":"991_CR112","doi-asserted-by":"publisher","first-page":"107183","DOI":"10.1016\/j.lungcan.2023.107183","volume":"179","author":"M Shirasawa","year":"2023","unstructured":"Shirasawa M, Yoshida T, Shiraishi K, Takigami A, Takayanagi D, Imabayashi T, et al. Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy. Lung Cancer. 2023;179:107183. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107183.","journal-title":"Lung Cancer"},{"issue":"23","key":"991_CR113","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1809064.","journal-title":"N Engl J Med"},{"key":"991_CR114","doi-asserted-by":"publisher","unstructured":"Bria E, Morgillo F, Garassino MC, Ciardiello F, Ardizzoni A, Stefani A, et al. Atezolizumab plus carboplatin and etoposide in patients with untreated extensive-stage small-cell lung cancer: interim results of the MAURIS phase IIIb trial. Oncologist. 2024;29(5):e690\u20138. https:\/\/doi.org\/10.1093\/oncolo\/oyad342.","DOI":"10.1093\/oncolo\/oyad342"},{"issue":"1","key":"991_CR115","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12943-024-02014-x","volume":"23","author":"M Xie","year":"2024","unstructured":"Xie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, O\u2019Brien C, et al. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024;23(1):115. https:\/\/doi.org\/10.1186\/s12943-024-02014-x.","journal-title":"Mol Cancer"},{"issue":"6","key":"991_CR116","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1158\/1535-7163.MCT-24-0050","volume":"24","author":"A Calles","year":"2025","unstructured":"Calles A, Calvo E, Santamar\u00eda Nu\u00f1ez G, Costanzo F, Guill\u00e9n MJ, Martinez Diez M, et al. Unveiling the mechanism of Lurbinectedin\u2019s action and its potential in combination therapies in Small cell lung cancer. Mol Cancer Ther. 2025;24(6):828\u201339. https:\/\/doi.org\/10.1158\/1535-7163.MCT-24-0050.","journal-title":"Mol Cancer Ther"},{"issue":"10495","key":"991_CR117","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","volume":"405","author":"L Paz-Ares","year":"2025","unstructured":"Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K, et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2025;405(10495):2129\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(25)01011-6.","journal-title":"Lancet"},{"issue":"4","key":"991_CR118","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/cancers13040727","volume":"13","author":"EH Knelson","year":"2021","unstructured":"Knelson EH, Patel SA, Sands JM. PARP inhibitors in small-cell lung cancer: rational combinations to improve responses. Cancers (Basel). 2021;13(4):727. https:\/\/doi.org\/10.3390\/cancers13040727.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"991_CR119","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.jtho.2019.04.026","volume":"14","author":"A Thomas","year":"2019","unstructured":"Thomas A, Vilimas R, Trindade C, Erwin-Cohen R, Roper N, Xi L, et al. Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a phase II study. J Thorac Oncol. 2019;14(8):1447\u201357. https:\/\/doi.org\/10.1016\/j.jtho.2019.04.026.","journal-title":"J Thorac Oncol"},{"key":"991_CR120","doi-asserted-by":"publisher","unstructured":"Arya Y, Dyer P, Hegi-Johnson F, Reguart N, Manochakian R. Updates in Small cell lung cancer treatment: No longer too Small to ignore\u2014A review of recent therapeutic advances. Am Soc Clin Oncol Educ Book. 2026;46(3):e524964. https:\/\/doi.org\/10.1200\/EDBK-26-524964.","DOI":"10.1200\/EDBK-26-524964"},{"issue":"1","key":"991_CR121","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jtho.2017.09.1951","volume":"13","author":"K Almodovar","year":"2018","unstructured":"Almodovar K, Iams WT, Meador CB, Zhao Z, York S, Horn L, et al. Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse. J Thorac Oncol. 2018;13(1):112\u201323. https:\/\/doi.org\/10.1016\/j.jtho.2017.09.1951.","journal-title":"J Thorac Oncol"},{"key":"991_CR122","doi-asserted-by":"publisher","unstructured":"Husain H, Pavlick DC, Fendler BJ, Madison RW, Decker B, Gjoerup O, et al. Tumor fraction correlates with detection of actionable variants across >23, 000 circulating tumor DNA samples. JCO Precis Oncol. 2022;6(6):e2200261. https:\/\/doi.org\/10.1200\/PO.22.00261.","DOI":"10.1200\/PO.22.00261"},{"issue":"1","key":"991_CR123","doi-asserted-by":"publisher","first-page":"11775","DOI":"10.1038\/s41598-023-38881-5","volume":"13","author":"J Seo","year":"2023","unstructured":"Seo J, Kumar M, Mason J, Blackhall F, Matsumoto N, Dive C, et al. Plasticity of circulating tumor cells in small cell lung cancer. Sci Rep. 2023;13(1):11775. https:\/\/doi.org\/10.1038\/s41598-023-38881-5.","journal-title":"Sci Rep"},{"issue":"1","key":"991_CR124","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13046-025-03434-3","volume":"44","author":"G Pasello","year":"2025","unstructured":"Pasello G, Pigato G, Scattolin D, Lando S, Potente S, Romualdi C, et al. Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS\/ML43257). J Exp Clin Cancer Res. 2025;44(1):178. https:\/\/doi.org\/10.1186\/s13046-025-03434-3.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"991_CR125","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13073-021-00898-8","volume":"13","author":"DWY Tsui","year":"2021","unstructured":"Tsui DWY, Cheng ML, Shady M, Yang JL, Stephens D, Won H, et al. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Med. 2021;13(1):96. https:\/\/doi.org\/10.1186\/s13073-021-00898-8.","journal-title":"Genome Med"},{"issue":"12","key":"991_CR126","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1158\/1078-0432.CCR-22-2242","volume":"29","author":"L Sivapalan","year":"2023","unstructured":"Sivapalan L, Iams WT, Belcaid Z, Scott SC, Niknafs N, Balan A, et al. Dynamics of sequence and structural cell-free DNA landscapes in small-cell lung cancer. Clin Cancer Res. 2023;29(12):2310\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2242.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"991_CR127","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.21037\/tlcr-23-665","volume":"12","author":"CT Maansson","year":"2023","unstructured":"Maansson CT, Meldgaard P, Sorensen BS. Can liquid biopsy dynamics stratify patients with small cell lung cancer? Transl Lung Cancer Res. 2023;12(12):2565\u201369. https:\/\/doi.org\/10.21037\/tlcr-23-665.","journal-title":"Transl Lung Cancer Res"},{"issue":"12","key":"991_CR128","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/1078-0432.CCR-23-0420","volume":"29","author":"B Pellini","year":"2023","unstructured":"Pellini B, Chaudhuri AA. ctDNA monitoring for small cell lung cancer: ready for prime time? Clin Cancer Res. 2023;29(12):2176\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0420.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"991_CR129","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.molmed.2024.08.004","volume":"31","author":"R Behrouzi","year":"2025","unstructured":"Behrouzi R, Clipson A, Simpson KL, Blackhall F, Rothwell DG, Dive C, et al. Cell-free and extrachromosomal DNA profiling of small cell lung cancer. Trends Mol Med. 2025;31(1):64\u201378. https:\/\/doi.org\/10.1016\/j.molmed.2024.08.004.","journal-title":"Trends Mol Med"},{"issue":"3","key":"991_CR130","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/cyto.10071","volume":"50","author":"BY Kularatne","year":"2002","unstructured":"Kularatne BY, Lorigan P, Browne S, Suvarna SK, Smith MO, Lawry J. Monitoring tumour cells in the peripheral blood of small cell lung cancer patients. Cytometry. 2002;50(3):160\u201367. https:\/\/doi.org\/10.1002\/cyto.10071.","journal-title":"Cytometry"},{"issue":"2","key":"991_CR131","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2353\/ajpath.2009.090078","volume":"175","author":"JM Hou","year":"2009","unstructured":"Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol. 2009;175(2):808\u201316. https:\/\/doi.org\/10.2353\/ajpath.2009.090078.","journal-title":"Am J Pathol"},{"issue":"10","key":"991_CR132","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1056\/NEJMoa1208962","volume":"369","author":"DR Aberle","year":"2013","unstructured":"Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, et al. Results of the two incidence screenings in the national lung screening trial. N Engl J Med. 2013;369(10):920\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1208962.","journal-title":"N Engl J Med"},{"key":"991_CR133","doi-asserted-by":"publisher","unstructured":"Ilie M, Hofman V, Long-Mira E, Selva E, Vignaud JM, Padovani B, et al. \u201cSentinel\u201d circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One. 2014;9(10):e111597. https:\/\/doi.org\/10.1371\/journal.pone.0111597.","DOI":"10.1371\/journal.pone.0111597"},{"issue":"19","key":"991_CR134","doi-asserted-by":"publisher","first-page":"8429","DOI":"10.7314\/APJCP.2014.15.19.8429","volume":"15","author":"J Zhang","year":"2014","unstructured":"Zhang J, Wang HT, Li BG. Prognostic significance of circulating tumor cells in small-cell lung cancer patients: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(19):8429\u201333. https:\/\/doi.org\/10.7314\/APJCP.2014.15.19.8429.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"991_CR135","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s12032-013-0755-9","volume":"30","author":"WL Shi","year":"2013","unstructured":"Shi WL, Li J, Du YJ, Zhu W-F, Wu Y, Hu Y-M, et al. CK-19 mRNA-positive cells in peripheral blood predict treatment efficacy and survival in small-cell lung cancer patients. Med Oncol. 2013;30(4):755. https:\/\/doi.org\/10.1007\/s12032-013-0755-9.","journal-title":"Med Oncol"},{"issue":"4","key":"991_CR136","doi-asserted-by":"publisher","first-page":"409","DOI":"10.21037\/tlcr.2017.07.05","volume":"6","author":"V Foy","year":"2017","unstructured":"Foy V, Fernandez-Gutierrez F, Faivre-Finn C, Dive C, Blackhall F. The clinical utility of circulating tumour cells in patients with small cell lung cancer. Transl Lung Cancer Res. 2017;6(4):409\u201317. https:\/\/doi.org\/10.21037\/tlcr.2017.07.05.","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"991_CR137","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrc2621","volume":"9","author":"B Psaila","year":"2009","unstructured":"Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9(4):285\u201393. https:\/\/doi.org\/10.1038\/nrc2621.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"991_CR138","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.arcmed.2016.10.003","volume":"47","author":"X Wang","year":"2016","unstructured":"Wang X, Ma K, Wang Y, He H, Hu J-F, Li W, et al. Evaluation of circulating tumor cells in predicting therapeutic response in small cell lung cancer patients. Arch Med Res. 2016;47(6):454\u201359. https:\/\/doi.org\/10.1016\/j.arcmed.2016.10.003.","journal-title":"Arch Med Res"},{"issue":"5","key":"991_CR139","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1200\/JCO.2010.33.3716","volume":"30","author":"JM Hou","year":"2012","unstructured":"Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. JCO. 2012;30(5):525\u201332. https:\/\/doi.org\/10.1200\/JCO.2010.33.3716.","journal-title":"JCO"},{"issue":"17","key":"991_CR140","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1200\/JCO.2010.32.4459","volume":"29","author":"JS Temel","year":"2011","unstructured":"Temel JS, Greer JA, Admane S, Gallagher ER, Jackson VA, Lynch TJ, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non\u2013small-Cell lung cancer: results of a randomized study of early palliative care. JCO. 2011;29(17):2319\u201326. https:\/\/doi.org\/10.1200\/JCO.2010.32.4459.","journal-title":"JCO"},{"issue":"1","key":"991_CR141","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/0269216308098799","volume":"23","author":"S Innes","year":"2009","unstructured":"Innes S, Payne S. Advanced cancer patients\u2019 prognostic information preferences: a review. Palliat Med. 2009;23(1):29\u201339. https:\/\/doi.org\/10.1177\/0269216308098799.","journal-title":"Palliat Med"},{"issue":"1","key":"991_CR142","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nm.4239","volume":"23","author":"L Carter","year":"2017","unstructured":"Carter L, Rothwell DG, Mesquita B, Smowton C, Leong HS, Fernandez-Gutierrez F, et al. Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat Med. 2017;23(1):114\u201319. https:\/\/doi.org\/10.1038\/nm.4239.","journal-title":"Nat Med"},{"issue":"9","key":"991_CR143","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1535-7163.MCT-12-1167","volume":"12","author":"G Kallergi","year":"2013","unstructured":"Kallergi G, Konstantinidis G, Markomanolaki H, Papadaki MA, Mavroudis D, Stournaras C, et al. Apoptotic circulating tumor cells in early and metastatic breast cancer patients. Mol Cancer Ther. 2013;12(9):1886\u201395. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-1167.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"991_CR144","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1002\/1878-0261.13765","volume":"19","author":"D Papakonstantinou","year":"2025","unstructured":"Papakonstantinou D, Roumeliotou A, Pantazaka E, Shaukat AN, Christopoulou A, Koutras A, et al. Integrative analysis of circulating tumor cells (CTCs) and exosomes from small-cell lung cancer (SCLC) patients: a comprehensive approach. Mol Oncol. 2025;19(7):2038\u201355. https:\/\/doi.org\/10.1002\/1878-0261.13765.","journal-title":"Mol Oncol"},{"key":"991_CR145","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3389\/fimmu.2020.02109","volume":"11","author":"ME Bianchi","year":"2020","unstructured":"Bianchi ME, Mezzapelle R. The chemokine receptor CXCR4 in cell proliferation and tissue regeneration. Front Immunol. 2020;11:2109. https:\/\/doi.org\/10.3389\/fimmu.2020.02109.","journal-title":"Front Immunol"},{"issue":"9","key":"991_CR146","doi-asserted-by":"publisher","first-page":"8307","DOI":"10.3390\/ijms24098307","volume":"24","author":"L Casalino","year":"2023","unstructured":"Casalino L, Talotta F, Matino I, Verde P. FRA-1 as a regulator of EMT and metastasis in breast cancer. IJMS. 2023;24(9):8307. https:\/\/doi.org\/10.3390\/ijms24098307.","journal-title":"IJMS"},{"issue":"8","key":"991_CR147","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41571-024-00914-x","volume":"21","author":"T Sen","year":"2024","unstructured":"Sen T, Takahashi N, Chakraborty S, Takebe N, Nassar AH, Karim NA, et al. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat Rev Clin Oncol. 2024;21(8):610\u201327. https:\/\/doi.org\/10.1038\/s41571-024-00914-x.","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"991_CR148","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-18-4140","volume":"25","author":"MD Chalishazar","year":"2019","unstructured":"Chalishazar MD, Wait SJ, Huang F, Ireland AS, Mukhopadhyay A, Lee Y, et al. MYC-driven small-cell lung cancer is metabolically distinct and vulnerable to arginine depletion. Clin Cancer Res. 2019;25(16):5107\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4140.","journal-title":"Clin Cancer Res"},{"key":"991_CR149","doi-asserted-by":"publisher","first-page":"103756","DOI":"10.1016\/j.ebiom.2021.103756","volume":"75","author":"V Llombart","year":"2022","unstructured":"Llombart V, Mansour MR. Therapeutic targeting of \u201cundruggable\u201d MYC. EBioMedicine. 2022;75:103756. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103756.","journal-title":"EBioMedicine"},{"issue":"3","key":"991_CR150","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","volume":"30","author":"E Garralda","year":"2024","unstructured":"Garralda E, Beaulieu ME, Moreno V, Casacuberta-Serra S, Mart\u00ednez-Mart\u00edn S, Foradada L, et al. MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nat Med. 2024;30(3):762\u201371. https:\/\/doi.org\/10.1038\/s41591-024-02805-1.","journal-title":"Nat Med"},{"key":"991_CR151","doi-asserted-by":"publisher","unstructured":"Conacci-Sorrell M, McFerrin L, Eisenman RN. An overview of MYC and its interactome. Cold Spring Harbor Perspectives Med. 2014;4(1):a014357. https:\/\/doi.org\/10.1101\/cshperspect.a014357.","DOI":"10.1101\/cshperspect.a014357"},{"key":"991_CR152","doi-asserted-by":"publisher","unstructured":"Halling-Brown MD, Bulusu KC, Patel M, Tym JE, Al-Lazikani B. canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Res. 2012, Jan;40(D1):D947\u201356. https:\/\/doi.org\/10.1093\/nar\/gkr881. Epub 2011 Oct 19. PMID: 22013161; PMCID: PMC3245005.","DOI":"10.1093\/nar\/gkr881"},{"issue":"11","key":"991_CR153","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1158\/0008-5472.CAN-19-2400","volume":"80","author":"H Zhao","year":"2020","unstructured":"Zhao H, Iqbal NJ, Sukrithan V, Nicholas C, Xue Y, Yu C, et al. Targeted inhibition of the E3 ligase SCFSkp2\/Cks1 has antitumor activity in RB1-deficient human and mouse small-cell lung cancer. Cancer Res. 2020;80(11):2355\u201367. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2400.","journal-title":"Cancer Res"},{"key":"991_CR154","doi-asserted-by":"publisher","first-page":"178129","DOI":"10.1016\/j.ejphar.2025.178129","volume":"1006","author":"EM Kamel","year":"2025","unstructured":"Kamel EM, Khadrawy SM, Allam AA, Ahmed NA, Aba Alkhayl FF, Lamsabhi AM. Targeting the Skp2\u2013Cks1 protein\u2013protein interaction: structures, assays, and preclinical inhibitors. Eur J PharmacolEuropean J Pharmacol. 2025;1006:178129. https:\/\/doi.org\/10.1016\/j.ejphar.2025.178129.","journal-title":"Eur J PharmacolEuropean J Pharmacol"},{"issue":"8","key":"991_CR155","doi-asserted-by":"publisher","first-page":"1700076","DOI":"10.1002\/bies.201700076","volume":"39","author":"D Zhao","year":"2017","unstructured":"Zhao D, DePinho RA. Synthetic essentiality: targeting tumor suppressor deficiencies in cancer. Bioessays. 2017;39(8):1700076. https:\/\/doi.org\/10.1002\/bies.201700076.","journal-title":"Bioessays"},{"issue":"17","key":"991_CR156","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1038\/s41388-021-01744-2","volume":"40","author":"PS Patel","year":"2021","unstructured":"Patel PS, Algouneh A, Hakem R. Exploiting synthetic lethality to target BRCA1\/2-deficient tumors: where we stand. Oncogene. 2021;40(17):3001\u201314. https:\/\/doi.org\/10.1038\/s41388-021-01744-2.","journal-title":"Oncogene"},{"issue":"5","key":"991_CR157","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.cell.2017.01.013","volume":"168","author":"T Wang","year":"2017","unstructured":"Wang T, Yu H, Hughes NW, Liu B, Kendirli A, Klein K, et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras. Cell. 2017;168(5):890\u2013903.e15. https:\/\/doi.org\/10.1016\/j.cell.2017.01.013.","journal-title":"Cell"},{"issue":"1","key":"991_CR158","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41573-025-01273-7","volume":"25","author":"E Gon\u00e7alves","year":"2026","unstructured":"Gon\u00e7alves E, Ryan CJ, Adams DJ. Synthetic lethality in cancer drug discovery: challenges and opportunities. Nat Rev Drug Discov. 2026;25(1):22\u201338. https:\/\/doi.org\/10.1038\/s41573-025-01273-7.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"991_CR159","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.trecan.2018.08.003","volume":"4","author":"CJ Ryan","year":"2018","unstructured":"Ryan CJ, Bajrami I, Lord CJ. Synthetic lethality and cancer \u2013 Penetrance as the Major barrier. Trends Cancer. 2018;4(10):671\u201383. https:\/\/doi.org\/10.1016\/j.trecan.2018.08.003.","journal-title":"Trends Cancer"},{"issue":"24","key":"991_CR160","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1016\/j.devcel.2025.07.023","volume":"60","author":"D Hong","year":"2025","unstructured":"Hong D, Lyu Y, Nayak R, Becker JS, Booker MA, Masuzawa K, et al. Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancer. Dev Cell. 2025;60(24):3462\u201379.e13. https:\/\/doi.org\/10.1016\/j.devcel.2025.07.023.","journal-title":"Dev Cell"},{"issue":"8","key":"991_CR161","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.ccell.2024.06.012","volume":"42","author":"L Duplaquet","year":"2024","unstructured":"Duplaquet L, So K, Ying AW, Pal Choudhuri S, Li X, Xu GD, et al. Mammalian SWI\/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer. Cancer Cell. 2024;42(8):1352\u201369.e13. https:\/\/doi.org\/10.1016\/j.ccell.2024.06.012.","journal-title":"Cancer Cell"},{"issue":"1","key":"991_CR162","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/1535-7163.MCT-24-0861","volume":"25","author":"UA Patel","year":"2026","unstructured":"Patel UA, Shi MY, Kazan JM, Nixon KCJ, Ran X, Nair SN, et al. CRISPR screen identifies HDAC3 as a novel radiosensitizing target in small cell lung cancer. Mol Cancer Ther. 2026;25(1):183\u201395. https:\/\/doi.org\/10.1158\/1535-7163.MCT-24-0861.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"991_CR163","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41580-022-00566-8","volume":"24","author":"JS Mattick","year":"2023","unstructured":"Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen LL, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24(6):430\u201347. https:\/\/doi.org\/10.1038\/s41580-022-00566-8.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"991_CR164","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41419-024-06576-y","volume":"15","author":"C Pandini","year":"2024","unstructured":"Pandini C, Pagani G, Tassinari M, Vitale E, Bezzecchi E, Saadeldin MK, et al. The pancancer overexpressed NFYC antisense 1 controls cell cycle mitotic progression through in cis and in trans modes of action. Cell Death Dis. 2024;15(3):206. https:\/\/doi.org\/10.1038\/s41419-024-06576-y.","journal-title":"Cell Death Dis"},{"key":"991_CR165","doi-asserted-by":"publisher","first-page":"216950","DOI":"10.1016\/j.canlet.2024.216950","volume":"592","author":"M Gugnoni","year":"2024","unstructured":"Gugnoni M, Lorenzini E, Torricelli F, Donati B, Manicardi V, Vitale E, et al. Linc00941 fuels ribogenesis and protein synthesis by supporting robust cMYC translation in malignant pleural mesothelioma. Cancer Lett. 2024;592:216950. https:\/\/doi.org\/10.1016\/j.canlet.2024.216950.","journal-title":"Cancer Lett"},{"issue":"1","key":"991_CR166","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41420-025-02546-1","volume":"11","author":"D Barnaba","year":"2025","unstructured":"Barnaba D, Franzese Canonico M, Helmer-Citterich M, Gandellini P, Melino G, Smirnov A, et al. LEADR, a p63 target, dampens interferon signalling in bladder cancer. Cell Death Discov. 2025;11(1):264. https:\/\/doi.org\/10.1038\/s41420-025-02546-1.","journal-title":"Cell Death Discov"},{"key":"991_CR167","doi-asserted-by":"publisher","unstructured":"Liu SJ, Horlbeck MA, Cho SW, Birk HS, Malatesta M, He D, et al. Crispri-based genome-scale identification of functional long noncoding RNA loci in human cells. Science. 2017;355(6320):aah7111. https:\/\/doi.org\/10.1126\/science.aah7111.","DOI":"10.1126\/science.aah7111"},{"issue":"4","key":"991_CR168","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41592-024-02190-0","volume":"21","author":"JJ Montero","year":"2024","unstructured":"Montero JJ, Trozzo R, Sugden M, \u00d6llinger R, Belka A, Zhigalova E, et al. Genome-scale pan-cancer interrogation of lncRNA dependencies using CasRx. Nat Methods. 2024;21(4):584\u201396. https:\/\/doi.org\/10.1038\/s41592-024-02190-0.","journal-title":"Nat Methods"},{"issue":"9","key":"991_CR169","doi-asserted-by":"publisher","first-page":"100171","DOI":"10.1016\/j.xgen.2022.100171","volume":"2","author":"R Esposito","year":"2022","unstructured":"Esposito R, Polidori T, Meise DF, Pulido-Quetglas C, Chouvardas P, Forster S, et al. Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities. Cell Genomics. 2022;2(9):100171. https:\/\/doi.org\/10.1016\/j.xgen.2022.100171.","journal-title":"Cell Genomics"},{"issue":"1","key":"991_CR170","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12943-024-02021-y","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang L, Bitar M, Lu X, Jacquelin S, Nair S, Sivakumaran H, et al. CRISPR-Cas13d screens identify KILR, a breast cancer risk-associated lncRNA that regulates DNA replication and repair. Mol Cancer. 2024;23(1):101. https:\/\/doi.org\/10.1186\/s12943-024-02021-y.","journal-title":"Mol Cancer"},{"issue":"16","key":"991_CR171","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1182\/blood.2023021991","volume":"144","author":"K Grillone","year":"2024","unstructured":"Grillone K, Ascrizzi S, Cremaschi P, Amato J, Poler\u00e0 N, Croci O, et al. An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma. Blood. 2024;144(16):1705\u201321. https:\/\/doi.org\/10.1182\/blood.2023021991.","journal-title":"Blood"},{"issue":"3","key":"991_CR172","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.molmed.2018.01.001","volume":"24","author":"G Arun","year":"2018","unstructured":"Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med. 2018;24(3):257\u201377. https:\/\/doi.org\/10.1016\/j.molmed.2018.01.001.","journal-title":"Trends Mol Med"},{"key":"991_CR173","doi-asserted-by":"publisher","first-page":"111565","DOI":"10.1016\/j.dib.2025.111565","volume":"60","author":"G Pagani","year":"2025","unstructured":"Pagani G, Pandini C, Tassinari M, Gandellini P. Integrating datasets to dissect NFYC-AS1 RNA- and transcription-dependent functions: comparative transcriptome profiling of knockdown strategies. Data Brief. 2025;60:111565. https:\/\/doi.org\/10.1016\/j.dib.2025.111565.","journal-title":"Data Brief"},{"key":"991_CR174","doi-asserted-by":"publisher","first-page":"145497","DOI":"10.1016\/j.gene.2021.145497","volume":"779","author":"D Tolomeo","year":"2021","unstructured":"Tolomeo D, Agostini A, Visci G, Traversa D, Storlazzi CT. PVT1: a long non-coding RNA recurrently involved in neoplasia-associated fusion transcripts. Gene. 2021;779:145497. https:\/\/doi.org\/10.1016\/j.gene.2021.145497.","journal-title":"Gene"},{"issue":"7512","key":"991_CR175","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/nature13311","volume":"512","author":"YY Tseng","year":"2014","unstructured":"Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature. 2014;512(7512):82\u201386. https:\/\/doi.org\/10.1038\/nature13311.","journal-title":"Nature"},{"issue":"6","key":"991_CR176","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41416-021-01584-7","volume":"126","author":"D Traversa","year":"2022","unstructured":"Traversa D, Simonetti G, Tolomeo D, Visci G, Macchia G, Ghetti M, et al. Unravelling similarities and differences in the role of circular and linear PVT1 in cancer and human disease. Br J Cancer. 2022;126(6):835\u201350. https:\/\/doi.org\/10.1038\/s41416-021-01584-7.","journal-title":"Br J Cancer"},{"issue":"10","key":"991_CR177","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.clon.2020.05.017","volume":"32","author":"V Vidhyasagar","year":"2020","unstructured":"Vidhyasagar V, Haq SU, Lok BH. Patient-derived xenograft models of small cell lung cancer for therapeutic development. Clin Oncol (R Coll Radiol). 2020. Clin Oncol. 2020;32(10):619\u201325. https:\/\/doi.org\/10.1016\/j.clon.2020.05.017.","journal-title":"Clin Oncol"},{"key":"991_CR178","doi-asserted-by":"publisher","first-page":"1211026","DOI":"10.3389\/fphar.2023.1211026","volume":"14","author":"C Sen","year":"2023","unstructured":"Sen C, Koloff CR, Kundu S, Wilkinson DC, Yang JM, Shia DW, et al. Development of a small cell lung cancer organoid model to study cellular interactions and survival after chemotherapy. Front Pharmacol. 2023;14:1211026. https:\/\/doi.org\/10.3389\/fphar.2023.1211026.","journal-title":"Front Pharmacol"},{"issue":"12","key":"991_CR179","doi-asserted-by":"publisher","first-page":"116595","DOI":"10.1016\/j.celrep.2025.116595","volume":"44","author":"H Terai","year":"2025","unstructured":"Terai H, Yasuda H, Sato T. Organoid-based precision cancer modeling: new frontier in lung cancer research. Cell Rep. 2025;44(12):116595. https:\/\/doi.org\/10.1016\/j.celrep.2025.116595.","journal-title":"Cell Rep"},{"issue":"8","key":"991_CR180","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41417-023-00608-z","volume":"30","author":"G Alyateem","year":"2023","unstructured":"Alyateem G, Wade HM, Bickert AA, Lipsey CC, Mondal P, Smith MD, et al. Use of CRISPR-based screens to identify mechanisms of chemotherapy resistance. Cancer Gene Ther. 2023;30(8):1043\u201350. https:\/\/doi.org\/10.1038\/s41417-023-00608-z.","journal-title":"Cancer Gene Ther"},{"key":"991_CR181","doi-asserted-by":"publisher","first-page":"1220376","DOI":"10.3389\/fcell.2023.1220376","volume":"11","author":"M Li","year":"2023","unstructured":"Li M, Sun J, Shi G. Application of CRISPR screen in mechanistic studies of tumor development, tumor drug resistance, and tumor immunotherapy. Front Cell Dev Biol. 2023;11:1220376. https:\/\/doi.org\/10.3389\/fcell.2023.1220376.","journal-title":"Front Cell Dev Biol"},{"key":"991_CR182","doi-asserted-by":"publisher","first-page":"1304425","DOI":"10.3389\/fgene.2023.1304425","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Khalil A, Kamar A, Du M, Dinh T, McFarland C, et al. Unveiling immune checkpoint regulation: exploring the power of in vivo CRISPR screenings in cancer immunotherapy. Front Genet. 2023;14:1304425. https:\/\/doi.org\/10.3389\/fgene.2023.1304425.","journal-title":"Front Genet"},{"issue":"1","key":"991_CR183","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-024-02068-x","volume":"23","author":"Y Oh","year":"2024","unstructured":"Oh Y, Kim S, Kim Y, Kim H, Jang D, Shin S, et al. Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy. Mol Cancer. 2024;23(1):155. https:\/\/doi.org\/10.1186\/s12943-024-02068-x.","journal-title":"Mol Cancer"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00991-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00991-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00991-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:49:24Z","timestamp":1788666564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00991-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":183,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["991"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00991-3","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"118"}}